Home » Stocks » ATRA

Atara Biotherapeutics, Inc. (ATRA)

Stock Price: $13.33 USD 0.05 (0.38%)
Updated Apr 19, 2021 2:27 PM EDT - Market open
Market Cap 1.11B
Revenue (ttm) n/a
Net Income (ttm) -306.62M
Shares Out 73.97M
EPS (ttm) -4.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $13.33
Previous Close $13.28
Change ($) 0.05
Change (%) 0.38%
Day's Open 13.20
Day's Range 13.05 - 13.49
Day's Volume 472,113
52-Week Range 7.45 - 28.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first o...

Other stocks mentioned: BLI, CGEN, CIDM, CRDF, KERN, ZDGE
2 weeks ago - InvestorPlace

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 weeks ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop ...

3 months ago - Business Wire

A Relative Strength Rating upgrade for Atara Biotherapeutics shows improving technical performance. The post Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating appeared first on...

3 months ago - Investors Business Daily

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformativ...

3 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop ...

3 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative...

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

4 months ago - Business Wire

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development and...

4 months ago - Business Wire

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 mont...

Other stocks mentioned: ALLO, BMY, CLLS, CRSP, GILD, NVS, PFE
4 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

Atara Biotherapeutics sees its Relative Strength Rating reach the elite 90-plus level.

7 months ago - Investors Business Daily

24/7 Wall St. reviews dozens of analyst research reports each day of the week, and most of the so-called Buy and Outperform ratings come with upside of 8% to 10% for Dow Jones industrials, S&P 500 and r...

7 months ago - 24/7 Wall Street

Week 38 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AXP, FVRR, HD, JNJ, JPM, KO ...
7 months ago - Seeking Alpha

Atara (ATRA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

7 months ago - Business Wire

When it comes to life-threatening illnesses, mesothelioma would rank close to the top of the list.

7 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

7 months ago - Business Wire

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

8 months ago - Business Wire

Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

8 months ago - Business Wire

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

8 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor of Atara Biotherapeutics

9 months ago - Zacks Investment Research

These companies offer promising pipelines that could deliver in the long term.

Other stocks mentioned: APRE
9 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative t...

9 months ago - Business Wire

Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

9 months ago - Zacks Investment Research

Atara Biotherapeutics Inc. (NASDAQ: ATRA) is finding itself caught between a rock and a hard place after Friday’s drug study news.

10 months ago - 24/7 Wall Street

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: DVAX, FIXX, GTHX, IMGN, KDMN, VKTX
10 months ago - Kiplinger

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

11 months ago - Zacks Investment Research

Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Atara Biotherapeutics Inc (ATRA) CEO Pascal Touchon on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: BHVN, CBAY, MRNS, PTCT, SLDB, TBIO
11 months ago - InvestorPlace

Amarin and Atara Biotherapeutics could both be diamonds in the rough.

Other stocks mentioned: AMRN
11 months ago - The Motley Fool

Atara Biotherapeutics: Still Bullish On Long-Term Prospects

1 year ago - Seeking Alpha

About ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies a... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2014
CEO
Pascal Touchon
Employees
437
Stock Exchange
NASDAQ
Ticker Symbol
ATRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is 35.57, which is an increase of 166.84% from the latest price.

Price Target
$35.57
(166.84% upside)
Analyst Consensus: Buy